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Gene expressionAbstract Lactobacillus (LB) and a-lipoic acid (ALA) were investigated to compare their protective
effects against dimethylnitrosamine (DMN)-induced liver ﬁbrosis in rats. Animals were either
injected intraperitoneally with DMN to induce hepatic ﬁbrosis, or were left untreated (negative con-
trol). For the DMN+ LB and DMN+ALA treatment groups, at two weeks of DMN treatment
LB or ALA was added to the feed and supplementation continued until the experimental endpoint
at sixty days. At the study endpoint, expression of IL-1b, IL-6, IL-10, TNF-a, IFN-c, TGF-b1,
COL1-a1 genes and the concentration of glutathione and malondialdehyde were measured in liver
tissues, while GOT, GPT, and ALP concentrations were measured in blood. Body weights remained
higher in NC and DMN+ LB groups compared to DMN and DMN+ALA groups, while activ-
ity of GOT and GPT in serum was lower in DMN+ LB and DMN+ALA groups compared to
the DMN group. Compared to other treatment groups, in the DMN group expression of both
TGF-b1 and, COL1-a1 mRNAs and pro-inﬂammatory cytokines increased, while that of 1L-10
decreased. Furthermore, LB and ALA treatments increased antioxidant activity of glutathione
and decreased malondialdehyde in comparison to the DMN group. Between LB and ALAabia.
136 K.M.A. Zoheir et al.treatments, glutathione concentration was higher in the DMN+ LB group, while malondialdehyde
was lower. Our results indicate that both LB and ALA exert hepatoprotective effects against
DMN-induced liver ﬁbrosis. Their beneﬁcial effects may be partly associated with down-regulation
of both TGF-b1 and COL1-a1 signaling, which may be accounted for reduction of increased
oxidative stress and TNF-a production.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Academy of Scientific Research &
Technology.1. Introduction
Under normal conditions, ﬁbrosis is a biological wound-
healing process initiated in response to an inﬂammatory reac-
tion. Chronic ﬁbrosis, however, can be pathological leading to
the formation of scar tissue, organ failure, and ultimately
death. Liver ﬁbrosis is usually initiated by hepatocyte damage,
resulting in the recruitment of inﬂammatory cells along with
activation of Kupffer cells and hepatic stellate cells (HSCs).
Friedman postulated that liver ﬁbrosis, a common conse-
quence of chronic liver injury, is induced by a variety of etio-
logical factors and can lead to liver cirrhosis [10,13]. This
progressive pathological process is characterized by the accu-
mulation of extracellular matrix (ECM) proteins. Activated
HSCs with a myoﬁbroblastic phenotype have a high prolifera-
tive index, and these cells release proﬁbrogenic cytokines [30],
and consequently produce ECM-related molecules such as
alpha-smooth muscle actin (a-SMA), collagen, and tissue
inhibitors of metalloproteinases (TIMPs) [11,58]. In addition,
it was suggested that the transforming growth factor-beta
(TGF-b) is a potent ﬁbrinogenic cytokine, which is increased
in local and systemic concentrations in response to acute and
chronic liver injury [46]. TGF-b acts as a triggering factor to
activate the HSCs and ﬁbroblasts to accelerate the accumula-
tion of extracellular matrix proteins [16]. Therefore, it is crucial
to explore therapeutic modalities that could potentially inhibit
or reverse the action of TGF-b and HSCs and consequently
inhibit the progression of hepatic ﬁbrosis [32,57].
Until recently, the ﬁbrotic process was considered to be
irreversible, but emerging clinical and experimental evidence
has revealed that cirrhosis is a potentially reversible process.
Probiotics exist naturally in various types of foods, partic-
ularly those that are fermented. According to Shah and Chow
the most popular probiotic strains are represented by the
following genera: Lactobacillus (LB), Streptococcus, and
Biﬁdobacterium [6,9,18,14,22,23,33,47,55,56]. Other organisms
including enterococci and yeasts have also been used as probi-
otics [66]. The mechanisms by which probiotics exert their
effects are largely unknown, but may involve modifying gut
pH, antagonizing pathogens through production of antimicro-
bial compounds, competing for pathogen binding and receptor
sites as well as for available nutrients and growth factors, stim-
ulating immunomodulatory cells, and producing lactase [56].
For example, Wang et al. concluded that probiotic LGG (Lac-
tobacillus rhamnosus GG, known as LGG) treatment reduced
alcohol-induced hepatic inﬂammation by attenuation of
TNF-a production via inhibition of TLR4- and TLR5-
mediated endotoxin activation [7,60]. Furthermore, Gram-
negative bacteria-derived endotoxemia, in conjunction with
impaired gut integrity, may be one of the mechanisms foractivating pro-inﬂammatory pathways leading to
adrenoleukodystrophy (ALD) [48].
Accumulating evidence suggests that the potential beneﬁt
following consumption of fermented dairy products containing
viable lactic acid bacteria is mainly attributable to the favor-
able alteration in GI micro-ecology [7,9,17]. Thus, probiotics
may be an avenue to provide a safe, cost effective, and natural
approach to add a barrier against microbial infection [31,56].
a-Lipoic acid (ALA) is an eight-carbon disulﬁde compound
[62] and functions as a natural cofactor in pyruvate and a-keto
dehydrogenase complexes [3,40]. ALA and its reduced form,
dihydrolipoic acid, act as potent antioxidants [53] that scav-
enge free radicals [3,36]. The antioxidant role of ALA has been
implicated in hepatitis, diabetes, atherosclerosis, urolithiasis,
HIV infection [59], and also in the treatment of acute liver poi-
soning, liver cirrhosis, heavy metal poisoning, and other liver
pathologies [3,4,42].
Oral administration of ALA was investigated by Pari and
Murugavel for its possible hepatoprotective effect against chlo-
roquine-induced toxicity in Wistar rats [43,50]. The results of
this study revealed that ALA could offer protection against
chloroquine-induced hepatotoxicity. Moreover, ALA exhibited
a greater protective effect when compared with silymarin, a ref-
erence drug [43]. In this study, we investigated and compared
supplementation of LB and ALA in rats treated with DMN,
as a means to assess their effects in liver ﬁbrosis. We have cho-
sen both LB and ALA due to their anti-oxidant and protective
effects according to many literatures. In addition, they are the
two most promising therapies. The results from this study are
promising and suggest the potential therapeutic importance
of using LB as a probiotic source to help mitigate ﬁbrosis.2. Materials and methods
2.1. Preparation of Lactobacillus sp.
Lactobacillus sp. is used in this study as a probiotic. The strain
was cultivated in 1 L NB medium for three day at 37 C at sta-
tic conditions. The CFU of the resulting culture was >108/ml.
Medium containing the Lactobacillus sp. was given to animals
at a concentration of 100 ml/kg food.
2.2. Animals
Adult male Wistar Albino rats aged approximately 3 months
and weighing 150 ± 10 g, were obtained from the Animal Care
Center, College of Pharmacy, King Saud University, Riyadh,
Saudi Arabia. The animals were housed in metabolic cages
under controlled environmental conditions (25 C and 12 h
light/dark cycle). They all had free access to pulverized
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study has been approved by the Research Ethics Committee
of College of Pharmacy, King Saud University, Riyadh, Saudi
Arabia.
2.3. Chemicals
DMN was purchased from Sigma Chemical, St. Louis, MO,
USA. a-Lipoic acid (ALA) was purchased from Sigma
Chemical, St. Louis, MO, USA. Kits for determination of
Glutamic-Oxaloacetic Transaminase (GOT), Glutamic-
Pyruvic Transaminase (GPT) and Alkaline phosphatase
(ALP) were purchased from USA – Randox Laboratories.
TRIzol reagent was purchased from Invitrogen (Grand
Island, NY, USA). High-Capacity cDNA reverse transcription
kits and SYBR Green PCR Master Mix were purchased from
Applied Biosystems (Foster City, CA, USA). The primers used
in the current study were purchased from MSAM
International Est, Riyadh, KSA.
2.4. Experimental design
Four groups with six albino rats each were used. All had free
access to rat pellets and water for 60 days. (1) Negative control
(NC) group: no treatment. (2) Positive control (DMN) group:
rats were injected intraperitoneally with dimethyl nitrosamine
(DMN) (10 mg/kg per day for 3 consecutive days per week
for the ﬁrst 4 weeks) to induce hepatic ﬁbrosis as according
to Weng et al. [61]. (3) DMN+ LB group: animals received
the same treatment as group 2. Additionally, starting from
the ﬁrst day and parallel to the treatment with DMN, animals
were supplemented with LB (1 · 108 CFU/ml) for the remain-
der of the study, which was 60 days in total. (4) DMN+ALA
group: rats received the same treatment as DMN group except
that, after 2 weeks of DMN treatment, they received an oral
gavage of ALA (100 mg/kg) dissolved in groundnut oil each
day for 10 days. After 60 days, the animals were left for 12 h
without feeding prior to sacriﬁce and collection of tissues for
analysis.
The weights of the rats were measured every 5 days, and at
the end of the 60th day rats were anesthetized using diethyl
ether, and a blood sample was collected from each rat. The
animals were then sacriﬁced. The abdominal cavity was imme-
diately opened and the liver was excised, weighed, and then
washed with cold 0.1 M phosphate buffer, pH 7.4.
2.5. Biochemical analysis
A blood sample was collected from each rat in a sterile eppen-
dorf tube, left to stand at room temperature (20 C) for 2 min
then centrifuged at 2000 rpm. As markers for liver ﬁbrosis,
GOT, GPT and ALP activities were determined spectrophoto-
metrically using Randox kit (Randox Laboratories-US, Ltd.,
Kearneysville, WV, USA). The increase in the absorbance
across time was measured at various time intervals and the best
slope determined for each sample. The activity from each slope
was determined against standard curves for each of GOT,
GPT and ALP.
2.6. RNA extraction and cDNA synthesis
Total RNA from the liver tissue homogenate was isolated
using TRIzol reagent (Invitrogen) according to themanufacturer’s instructions and quantiﬁed by measuring the
absorbance at 260 nm. The RNA quality was determined by
measuring the 260/280 ratio. The cDNA synthesis was per-
formed using the High-Capacity cDNA reverse transcription
kit (Applied Biosystems) according to the manufacturer’s
instructions. Brieﬂy, 1.5 lg of total RNA from each sample
was added to a mixture of 2.0 ll of 10x reverse transcriptase
buffer, 0.8 ll of 25· dNTP mix (l00 mM), 2.0 ll of l0· reverse
transcriptase random primers, 1.0 ll of MultiScribe reverse
transcriptase, and 3.2 ll of nuclease-free water. The ﬁnal reac-
tion mixture was kept at 25 C for 10 min, heated to 37 C for
120 min, heated for 85 C for 5 s, and ﬁnally cooled to 4 C.
2.7. Quantiﬁcation of mRNA expression by real-time
polymerase chain reaction (RT-PCR)
Quantitative analysis of mRNA expression of target genes
which are considered markers for liver ﬁbrosis and injury
was performed by RT-PCR through subjecting the resultant
cDNA from the above preparation to PCR ampliﬁcation using
96-well optical reaction plates in the ABI Prism 7500 System
(Applied Biosystems). The 25-ll reaction mixture contained
0.1 ll of 10 lM forward primer and 0.1 ll of 10 lM reverse
primer (40 lM ﬁnal concentration of each primer), 12.5 ll of
SYBR Green Universal Master mix, 11.05 ll of nuclease-free
water, and 1.25 ll of cDNA sample. The primers used in the
current study were chosen from pubmed.com (http://
www.ncbi.nlm.nih.gov/tools/primer-blast) as listed in Table 1.
Assay controls were incorporated onto the same plate, namely,
no-template controls to test for the contamination of any assay
reagents. The real-time PCR data have been analyzed using the
relative gene expression (i.e., A¨A¨CT) method, as described in
Applied Biosystems, User Bulletin No. 2. Brieﬂy, the data
are presented as the fold change in gene expression normalized
to the endogenous reference gene (GAPDH) and relative to a
calibrator.
2.8. Reduced glutathione (GSH) and malondialdehyde (MDA)
analysis
At the end of the treatment period (60 days), animals were sac-
riﬁced after an overnight fast, under ether anesthesia. The liver
Figure 1 Body weight averages among different treatment
groups over the duration of study. NC, negative controls;
DMN, dimethylnitrosamine alone; DMN+ LB, DMN plus
Lactobacillus, and DMN+ALA, DMN plus a-lipoic acid. Values
are mean ± SE from six animals per group.
Figure 2 Quantitation of liver function enzymes in sera at the
study endpoint. NC, negative controls; DMN, dimethylnitrosa-
mine alone; DMN+ LB, DMN plus Lactobacillus species;
DMN+ALA, DMN plus a-lipoic acid. Values are mean ± SE
from six animals per group. Different letters indicate signiﬁcant
differences (P< 0.05, ANOVA, LSD posthoc).
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cessed for biochemical measurements. The tissues were then
homogenized in ice-cold 0.15 M KCI with a homogenizer at
16,000 rpm for 3 min. The homogenates were centrifuged
at 4000 rpm at 4 C for 1 h. The supernatants were stored at
40 C until they were analyzed.
Reduced glutathione level was evaluated as an additional
marker for liver ﬁbrosis according to Nabavi et al. and Beutler
et al. [2,38]. The homogenate sample (720 lL) was diluted and
then trichloroacetic acid (5%) was added to the reaction mix-
ture for precipitation of protein content in tissue homogenates.
Reaction was centrifuged at 10,000 g for 5 min and then the
supernatant was transferred into a clean tube into which
Ellman’s reagent [5,5:dithiobis(2-nitrobenzoicacid)solution]
was added. Finally, the absorbance at wave length of 417 nm
was recorded. Lipid peroxidation was carried out by measur-
ing malondialdehyde (MDA) as follows: The reaction mixture
was prepared by adding 1 ml homogenate to 4 ml reaction
solution (15% trichloroacetic acid:0.375% thiobarbituric
acid:0.25 N NaOH, 1:1:1, w/v) and heating at 100 C for
10 min. The mixture was cooled to room temperature, centri-
fuged (10,000 g for 10 min) and the absorbance of the superna-
tant was recorded at 532 nm.
2.9. Statistical analysis
Data are presented as mean ± SE. The data from each of the
measured parameters (GOT, GPT, ALP, GSH, MDA as well
the gene expressions have been subjected to analysis using
ANOVA to determine the P-value for the different measured
variables. The Fisher’s least signiﬁcant difference (LSD) test
was used within this method 5.0% risk of calling each pair
of means signiﬁcantly different when the actual difference
equal to 0.01 to ﬁnd the signiﬁcant differences among different
groups.
3. Results
3.1. Body weight in rats
To assess the protective effects of LB and ALA against liver
damage induced by DMN, the average body weights of rats
were compared for 60 days of treatment As expected, the aver-
age body weight of the DMN group was markedly lower over
time (P< 0.01) than that of the negative control group (NC
group) (Fig. 1). Notably, body weights of the DMN+ LB
group did not differ from those of the NC group suggesting
that the probiotic provided effective protection against
DMN. However, body weights of the ALA+ DMN treated
group decreased (P< 0.05) over the ﬁrst 3 weeks of treatment
then started to increase gradually after day 45 of study to a
level greater than the initial body weight, yet lower than the
NC or DMN+ LB groups.
3.2. Examination of liver function
In order to assess liver function, the liver enzymes GOT, GPT,
and ALP were assessed in peripheral blood (Fig. 2). The activ-
ities of these three enzymes increased in the DMN group in
comparison to the LB + DMN, ALA+DMN, and NCgroups. In contrast, no signiﬁcant differences were observed
between the NC and DMN+ LB groups (P> 0.05); however
all liver function enzymes assessed in the ALA+ DMN group
were signiﬁcantly increased over NC (P< 0.05) (Fig. 2).
3.3. Cytokine production and gene expression levels
The expression of genes for transforming growth factor beta 1
(TGF-b1) and collagen type I alpha 1 (COL1-a1) as a markers
for occurrence of liver ﬁbrosis were higher in the DMN group
Figure 3 Expression of TGF-b1 and Col1a1 mRNAs in liver
tissues of different treatment groups at the study endpoint. NC,
negative controls; DMN, dimethylnitrosamine alone;
DMN+ LB, DMN plus Lactobacillus species; DMN+ ALA,
DMN plus a-lipoic acid. Quantitative RT-PCR values are shown
as mean ± SE normalized to the endogenous control (GAPDH)
for six animals per group. Different letters indicate signiﬁcant
differences (P< 0.05, ANOVA, LSD posthoc).
Figure 4 Expression of IL-1b, IL-6, and IL-10 mRNAs in liver
tissues at the study endpoint. NC, negative controls; DMN,
dimethylnitrosamine alone; DMN+ LB, DMN plus Lactobacil-
lus species; DMN+ ALA, DMN plus a-lipoic acid. Quantitative
RT-PCR values are shown as the mean ± SE normalized to the
endogenous control (GAPDH) for six animals per group. Differ-
ent letters indicate signiﬁcant differences (P< 0.05, ANOVA,
LSD posthoc).
Figure 5 Eexpression of TNF-a and IFN-c mRNAs in liver
tissues at the study endpoint. NC, negative controls; DMN,
dimethylnitrosamine alone; DMN+ LB, DMN plus Lactobacil-
lus species; DMN+ ALA, DMN plus a-lipoic acid. Quantitative
RT-PCR values are shown as the mean ± SE normalized to the
endogenous control (GAPDH) from six animals per group.
Different letters indicate signiﬁcant differences (P< 0.05,
ANOVA, LSD posthoc).
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groups (Fig. 3); however, no signiﬁcant differences were
observed between DMN+ LB and DMN+ALA groups,
or the NC group (P> 0.05). The expression of IL-1b, IL-6,
and IL-10 mRNAs was lower in the DMN group
(P< 0.001) compared to that seen in the DMN+ LB,
DMN+ALA, and NC groups (Fig. 4). Furthermore, the
expression of tumor necrosis factor-a (TNF-a) and interferon
gamma (IFN-c) mRNAs was higher in the DMN group than
in the DMN+ LB, DMN+ALA, and NC groups (Fig. 5).
Additionally, no signiﬁcant differences were observed between
DMN+ LB, DMN+ALA, or NC groups (P< 0.05).
3.4. Lipid peroxidation and GSH level
The activities of glutathione (GSH) and MDA in liver tissues
of all groups were evaluated and are depicted in Fig. 6. When
compared to DMN+ LB, DMN+ALA, and NC groups,
the GSH decreased in the DMN group (P< 0.05), whereas,
MDA increased (P< 0.05). In DMN+ LB group, the con-
centration of GSH was higher (P< 0.05) while MDA was
lower (P< 0.05) when compared to the DMN+ ALA group
(P< 0.05).
4. Discussion
This study investigated the roles of Lactobacillus as a probiotic
and a lipoic acid (ALA) as an antioxidant in the prevention of
the liver ﬁbrosis in rats. Measurement of body weight is a good
prognosticator of animal health and we found LB supplemen-
tation to have a positive effect on animal weight maintenance,
and thus health, even after treatment with the DMN.
Whereas the antioxidant ALA was associated with an ini-
tial decrease in the animal weight followed by a subsequentincrease and apparent recovery, after three weeks of treatment
reaching a pre-treatment weight by the end of study. There-
fore, while antioxidant treatment proved beneﬁcial in the
recovery from liver ﬁbrosis in rats, probiotic treatment appears
to inhibit the damage caused by DMN to overall health from
the onset. Further study will be required to determine the
precise mechanisms underlying this effect.
Figure 6 Concentration of malondialdehyde (MDA) and gluta-
thione (GSH) in liver tissues at the study endpoint. NC, negative
controls; DMN, dimethylnitrosamine alone; DMN+ LB, DMN
plus Lactobacillus species; DMN+ ALA, DMN plus a-lipoic
acid. Values are mean ± SE from 6 animals in each group.
Different values indicate signiﬁcant differences (P< 0.05,
ANOVA, LSD posthoc).
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ALA could attenuate progression of ﬁbrosis in DMN-induced
hepatic ﬁbrosis in animal models by inhibiting expression of
TGF-b1 and other inﬂammatory factors including TNF,
IFN-c, IL-1b and IL-6. In addition, we showed LB and
ALA attenuated TGF-b1 induced hepatic cell activation by
attenuating the upregulation of IL-10. TGF-b1, a potent ﬁbri-
nogenic cytokine, is increased both locally and systemically in
response to acute and chronic liver injury [24,46]. Moreover,
TGF-b1 accelerates the accumulation of extracellular matrix
proteins and thus, acts as a triggering factor to activate HSCs
and ﬁbroblasts [16,27]. TGF-b1 is a homodimeric protein that
regulates numerous cellular responses such as proliferation,
differentiation, migration, and apoptosis through the Smad
signaling pathways [1,29]. Our results show that both
TGF-b1 and type I alpha 1 collagen are markedly upregulated
in DMN-treated animals, and both LB and ALA treatments
successfully diminish the expression of both of these genes to
a level similar to that seen in the negative control group. Fur-
thermore, both LB and ALA were found to exert anti-ﬁbrotic
effects by decreasing the expression of collagen (col1a1) and
IFN-c in rats with DMN-induced liver ﬁbrosis likely through
the inhibition of PI3K/Akt signaling.
Treatment with DMN led to increased expression of IL-1b
and IL-6, likely as a result of decreased expression of IL-10;
however, supplementation with LB reversed this effect. Simi-
larly, ALA supplementation during DMN injection regulated
the expression level of these genes in a manner similar to LB
supplementation although both were lower in the magnitude
than that seen in the NC group. Furthermore, treatment with
DMN alone caused a signiﬁcant increase in the expression of
IFN-c and TNF-a mRNAs in comparison to that seen in all
other groups. The anti-inﬂammatory cytokine IL-10 has beenshown to promote tumor vascularization and growth in
immune-deﬁcient rats and to mediate antitumor effects in
immune-competent rats [43]. During immune regulation,
IL-1b and IL-6 act as pleiotropic cytokines to exert either
immunosuppressive or immunostimulatory effects on a variety
of cell types. It has been reported that IL-10 diminishes
secretion of TNF-a, IL-6, and macrophage inﬂammatory
protein-1b (MIP-1b) following lipopolysaccharide (LPS)
challenge of neutrophils [5]. In contrast, both LB and ALA
likely act as immune-response modiﬁers in vivo since they
inhibited intrahepatic expression of TNF-a.
When the liver cell plasma membrane is damaged, a variety
of enzymes normally located in the cytosol are released into the
bloodstream [35,37,39]. The quantitation of these enzymes in
serum is thus a useful marker of the extent and type of hepa-
tocellular damage. Increases of GOT and GPT levels in periph-
eral blood indicate the presence of an inﬂammatory state in
liver cells and chronic hepatic inﬂammation may lead to hepa-
tic ﬁbrosis. In the present study, DMN injection leads to
increased serum GOT and GPT levels; however, supplementa-
tion with either LB or ALA signiﬁcantly normalized GOT and
GPT levels possibly indicating an enhancement of liver cell
regeneration. According to the peripheral assessment of liver
function, LB showed more potent hepato-protective effects
against DMN than did ALA, although our results may suggest
that both LB and ALA offer protection against DMN
challenge by preserving the structural integrity of the hepato-
cellular membrane. The above ﬁndings are in agreement with
previous reports indicating that treatment with Picroliv [8]
Jigirine [64] and Neem leaf extract [51,61] signiﬁcantly reduced
the levels of serum markers in paracetamol-induced
hepatotoxicity.
The antioxidant efﬁcacy of both LB and ALA against
DMN induced oxidative stress was evaluated previously.
Treatment with DMN alone was found to result in a signiﬁ-
cant reduction in GSH concentration in liver tissue indicating
the presence of oxidative tissue damage in agreement with pre-
vious reports [19,34].
In the present study, supplementation with either LB or
ALA during DMN treatment restored GSH levels to normal
GSH. Further, we observed a signiﬁcant increase in MDA lev-
els in response to DMN treatment, which is in agreement with
previous reports [52,54]. An increased MDA level in liver tis-
sues suggests enhanced lipid peroxidation and downstream tis-
sue damage and failure of antioxidant defense mechanisms
[54]. Our results showed that LB supplementation signiﬁcantly
inhibited MDA production, implying a reduction in lipid per-
oxidation and protection of the tissues against DMN-induced
oxidative damage.
Several experiments have indicated that a common link
between chronic liver damage and hepatic ﬁbrosis may be oxi-
dative stress [45,63]. In addition, free radical production dur-
ing oxidative stress may lead to lipid peroxidation of
biological membranes, resulting in severe cell damage, and
playing a signiﬁcant role in the pathogenesis of disease. Our
ﬁndings are in agreement with those of Parola and Robino
[41,44] indicating that certain lipid peroxidation products
induce overexpression of ﬁbrogenic cytokine mRNAs and
increase the synthesis of collagen by initiating the activation
of hepatic stellate cells. Therefore, administering free radical
scavengers and reducing oxidative stress may cause a reduction
in hepatic ﬁbrosis progression [44]. Our results are in
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DMN-treated rats exhibited increased MDA levels in liver
homogenates. Furthermore, it is feasible that the inhibitory
activities of LB and ALA against DMN-induced hepatic ﬁbro-
sis are related, at least in part, through their antioxidant and
free radical scavenging abilities [34].
Study of Yuzhen et al. showed that oral administration of
LcZ suppressed iNOS activity in LPS/D-GalN-challenged rats
[49,65]. The above results indicate that the inhibition of iNOS/
NO production is presumably associated with the decreased
hepatic damage in LcZ-treated rats [65].
Many studies have shown that treatment with lactobacilli
can inhibit LPS-induced NF-jB signaling in cell lines
[1,21,59] and some studies showed that lactobacilli supplemen-
tation decreased NF-jB activity both in UC animal models
and UC patients [12,26].
It is well established that GSH acts as an essential intracel-
lular reducing agent for maintenance of antioxidant molecules
and the thiol groups on intracellular proteins (Ca2-ATPase
transporter of endoplasmic reticulum) [15,25], indicated that
naringenin, one of the ﬂavonoids, inhibits DMN-induced liver
damage in rats. Furthermore, GSH is potentially the most
important protective biomolecule against chemically-induced
cytotoxicity due to its ability to eliminate reactive intermedi-
ates via conjugation and hydroperoxide reduction and through
direct quenching of free radicals [20,28]. Therefore, increased
GSH in the liver, as seen with LB and ALA supplementation,
may be one of the factors responsible for inhibition of lipid
peroxidation.
In summary, animals treated solely with DMN suffer pro-
found cytotoxic and genotoxic effects; however, when animals
were supplemented with LB and ALA during DMN treatment
both cytotoxicity and genotoxicity were diminished. Thus,
both LB and ALA supplementation inhibited the cytotoxic
and genotoxic risks associated with DMN treatment in rats.
The present study demonstrates that both LB and ALA exert
in vivo hepatoprotective and anti-ﬁbrotic effects against
DMN-induced liver ﬁbrosis in rats. Moreover, the ability of
hepatoprotective and anti-ﬁbrotic activities of LB at the con-
centrations tested is higher than that of ALA. Both LB and
ALA demonstrated anti-inﬂammatory and anti-ﬁbrotic
activities followed by anti-oxidant activity via enhancement
of GSH production, enhancement of liver cell regeneration
and optimal regulation of TGF-b1, Col1-a1, IL-1b, IL-6,
IL-10, IFN-c, and TNF-a.
In conclusion, our results indicate that both LB and
ALA exert hepatoprotective effects against DMN-induced
liver ﬁbrosis but LB is more efﬁcient. Their beneﬁcial
effects may be partly associated with down-regulation of
TGF-b1 signaling, which may be accounted for reduction
of increased oxidative stress and TNF-a production. Hence,
our ﬁndings raise the possibility of the use of LB in the
treatment of some of liver diseases through its anti-oxida-
tive capacities.
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